NEOPRISM‑CRC: Nine weeks of pembrolizumab before surgery left 32 UK MMR‑deficient/MSI‑high bowel cancer patients relapse‑free after nearly three years
A UK trial called NEOPRISM‑CRC gave 32 people with stage 2 or 3 MMR‑deficient/MSI‑high bowel cancer a nine‑week course of…